The FDA's approval of Novitium Pharma's generic Pimozide represents a significant shift in the competitive landscape for this therapeutic area. Portfolio teams must evaluate the implications for pricing and market share among existing branded products to maintain competitive positioning. Regulatory context from FDA (FDA AP — PIMOZIDE (ORIG)) supports the near-term read. Assessment grounded in 18 ranked evidence items (6 high-relevance).